Bio-Techne Corp
TECH54.730USD
-2.980-5.16%
Close 07/31, 16:00（ET）Quotes delayed by 15 min
8.58BMarket Cap
65.17P/E TTM
More Details of Bio-Techne Corp Company
Bio-Techne Corporation is a global life sciences company providing tools and bioactive reagents for the research and clinical diagnostic communities. The Company's products assist scientific investigations into biological processes and the nature and progress of specific diseases. The Company, in partnership with Wilson Wolf, is creating products such as media and cytokines that are specifically tailored to G-Rex Bioreactors. Its segments include Protein Sciences and Diagnostics and Genomics. The Protein Sciences segment is a developer and manufacturer of biological reagents used in all aspects of life science research, diagnostics and cell and gene therapy. This segment also includes proteomic analytical tools, both manual and automated. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for the regulated diagnostics market, exosome-based molecular diagnostic assays, and tissue biopsy analysis.
Company Info
Ticker SymbolTECH
Company nameBio-Techne Corp
IPO dateFeb 09, 1989
Founded at1981
CEOMr. Kim Kelderman
Number of employees3100
Security typeOrdinary Share
Fiscal year-endFeb 09
Address614 Mckinley Pl N E
CityMINNEAPOLIS
Stock exchangeNASDAQ Global Select Consolidated
CountryUnited States of America
Postal code55413
Phone16123792956
Websitehttps://www.bio-techne.com/
Ticker SymbolTECH
IPO dateFeb 09, 1989
Founded at1981
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. John L. Higgins
Mr. John L. Higgins
Independent Director
Independent Director
60.20K
+24.90%
Mr. Kim Kelderman
Mr. Kim Kelderman
President, Chief Executive Officer, Chief Operating Officer, Director
President, Chief Executive Officer, Chief Operating Officer, Director
45.24K
+20.60%
Mr. Robert V. (Bob) Baumgartner, CPA
Mr. Robert V. (Bob) Baumgartner, CPA
Independent Chairman of the Board
Independent Chairman of the Board
44.86K
+3.37%
Dr. Roeland Nusse, Ph.D.
Dr. Roeland Nusse, Ph.D.
Independent Director
Independent Director
44.56K
+3.39%
Dr. Joseph D. (Joe) Keegan, Ph.D.
Dr. Joseph D. (Joe) Keegan, Ph.D.
Independent Director
Independent Director
13.77K
+11.88%
Dr. Rupert J. Vessey, Ph.D.
Dr. Rupert J. Vessey, Ph.D.
Independent Director
Independent Director
9.35K
+18.54%
Ms. Julie L. Bushman
Ms. Julie L. Bushman
Independent Director
Independent Director
7.13K
+25.77%
Mr. Shane Bohnen
Mr. Shane Bohnen
Senior Vice President, General Counsel, Corporate Secretary
Senior Vice President, General Counsel, Corporate Secretary
3.19K
+90.01%
Dr. Matthew F. Mcmanus
Dr. Matthew F. Mcmanus
President - Diagnostics and Genomics Segment
President - Diagnostics and Genomics Segment
2.98K
--
Dr. Judith V. Klimovsky, M.D.
Dr. Judith V. Klimovsky, M.D.
Independent Director
Independent Director
2.14K
+215.00%
View more
Name
Name/Position
Position
Shareholding
Change
Mr. John L. Higgins
Mr. John L. Higgins
Independent Director
Independent Director
60.20K
+24.90%
Mr. Kim Kelderman
Mr. Kim Kelderman
President, Chief Executive Officer, Chief Operating Officer, Director
President, Chief Executive Officer, Chief Operating Officer, Director
45.24K
+20.60%
Mr. Robert V. (Bob) Baumgartner, CPA
Mr. Robert V. (Bob) Baumgartner, CPA
Independent Chairman of the Board
Independent Chairman of the Board
44.86K
+3.37%
Dr. Roeland Nusse, Ph.D.
Dr. Roeland Nusse, Ph.D.
Independent Director
Independent Director
44.56K
+3.39%
Dr. Joseph D. (Joe) Keegan, Ph.D.
Dr. Joseph D. (Joe) Keegan, Ph.D.
Independent Director
Independent Director
13.77K
+11.88%
Dr. Rupert J. Vessey, Ph.D.
Dr. Rupert J. Vessey, Ph.D.
Independent Director
Independent Director
9.35K
+18.54%
Revenue Breakdown
Currency: USDUpdated: Sun, Jul 6
Currency: USDUpdated: Sun, Jul 6
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2021
FY2020
FY2019
By BusinessUSD
Name
Revenue
Proportion
Consumables
257.79M
81.53%
Service
27.25M
8.62%
Instruments
26.11M
8.26%
Royalty
5.04M
1.59%
By RegionUSD
Name
Revenue
Proportion
United States
181.92M
57.54%
EMEA, excluding U.K
66.50M
21.03%
Greater China
24.48M
7.74%
APAC, excluding Greater China
21.25M
6.72%
United Kingdom
12.85M
4.06%
Rest of World
9.18M
2.90%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Consumables
257.79M
81.53%
Service
27.25M
8.62%
Instruments
26.11M
8.26%
Royalty
5.04M
1.59%
Shareholding Stats
Updated: Wed, May 14
Updated: Wed, May 14
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
11.77%
T. Rowe Price Associates, Inc.
7.11%
BlackRock Institutional Trust Company, N.A.
5.94%
State Street Global Advisors (US)
4.17%
Select Equity Group, L.P.
3.42%
Other
67.59%
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
11.77%
T. Rowe Price Associates, Inc.
7.11%
BlackRock Institutional Trust Company, N.A.
5.94%
State Street Global Advisors (US)
4.17%
Select Equity Group, L.P.
3.42%
Other
67.59%
Shareholder Types
Shareholders
Proportion
Investment Advisor
58.62%
Investment Advisor/Hedge Fund
36.42%
Hedge Fund
2.69%
Research Firm
2.30%
Bank and Trust
2.19%
Pension Fund
1.92%
Sovereign Wealth Fund
1.32%
Individual Investor
1.06%
Insurance Company
0.25%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
1204
167.89M
107.09%
+2.47M
2025Q1
1245
168.10M
107.22%
+1.54M
2024Q4
1233
162.21M
102.61%
-6.39M
2024Q3
1205
159.40M
100.49%
-10.21M
2024Q2
1207
160.52M
101.86%
-12.24M
2024Q1
1216
162.56M
103.40%
-7.57M
2023Q4
1229
159.70M
100.98%
-3.97M
2023Q3
1217
156.41M
98.84%
-7.93M
2023Q2
1213
155.36M
98.68%
-4.04M
2023Q1
1206
153.08M
97.33%
-5.18M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
The Vanguard Group, Inc.
18.46M
11.77%
-66.38K
-0.36%
Mar 31, 2025
T. Rowe Price Associates, Inc.
11.14M
7.11%
+717.26K
+6.88%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
9.31M
5.94%
+50.72K
+0.55%
Mar 31, 2025
State Street Global Advisors (US)
6.53M
4.17%
+57.21K
+0.88%
Mar 31, 2025
Select Equity Group, L.P.
5.37M
3.42%
+3.03M
+129.77%
Mar 31, 2025
Geode Capital Management, L.L.C.
4.09M
2.61%
+92.10K
+2.30%
Mar 31, 2025
Atlanta Capital Management Company, L.L.C.
3.72M
2.37%
+771.93K
+26.18%
Mar 31, 2025
Baron Capital Management, Inc.
3.28M
2.09%
-861.18K
-20.82%
Mar 31, 2025
Neuberger Berman, LLC
3.03M
1.93%
-555.75K
-15.52%
Mar 31, 2025
MFS Investment Management
2.99M
1.91%
+472.36K
+18.75%
Mar 31, 2025
View more
Related ETFs
Updated: Sun, Jul 6
Updated: Sun, Jul 6
Name
Proportion
Global X Genomics & Biotechnology ETF
4.11%
Invesco Biotechnology & Genome ETF
2.19%
VanEck Biotech ETF
1.7%
Hilton Small-MidCap Opportunity ETF
1.54%
Thrivent Small-Mid Cap ESG ETF
1.46%
Invesco S&P 500 Equal Weight Health Care ETF
1.38%
WisdomTree BioRevolution Fund
1.2%
iShares Health Innovation Active ETF
1.14%
Nuveen ESG Mid-Cap Growth ETF
1.1%
VanEck Morningstar SMID Moat ETF
1.07%
View more
Global X Genomics & Biotechnology ETF
Proportion4.11%
Invesco Biotechnology & Genome ETF
Proportion2.19%
VanEck Biotech ETF
Proportion1.7%
Hilton Small-MidCap Opportunity ETF
Proportion1.54%
Thrivent Small-Mid Cap ESG ETF
Proportion1.46%
Invesco S&P 500 Equal Weight Health Care ETF
Proportion1.38%
WisdomTree BioRevolution Fund
Proportion1.2%
iShares Health Innovation Active ETF
Proportion1.14%
Nuveen ESG Mid-Cap Growth ETF
Proportion1.1%
VanEck Morningstar SMID Moat ETF
Proportion1.07%
Dividend
A total of
249.41M
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
Feb 05, 2025
TECH.NB Interim Cash Dividend of gross USD 0.08 paid on Feb 28, 2025 going ex on Feb 14, 2025
Feb 17, 2025
Feb 28, 2025
Feb 14, 2025
Oct 30, 2024
TECH.NB Final Cash Dividend of gross USD 0.08 paid on Nov 22, 2024 going ex on Nov 08, 2024
Nov 11, 2024
Nov 22, 2024
Nov 08, 2024
Aug 07, 2024
TECH.NB Interim Cash Dividend of gross USD 0.08 paid on Aug 30, 2024 going ex on Aug 19, 2024
Aug 19, 2024
Aug 30, 2024
Aug 19, 2024
May 01, 2024
TECH.NB Interim Cash Dividend of gross USD 0.08 paid on May 24, 2024 going ex on May 10, 2024
May 13, 2024
May 24, 2024
May 10, 2024
Feb 01, 2024
TECH.NB Interim Cash Dividend of gross USD 0.08 paid on Feb 26, 2024 going ex on Feb 09, 2024
Feb 12, 2024
Feb 26, 2024
Feb 09, 2024
Oct 31, 2023
TECH.NB Final Cash Dividend of gross USD 0.08 paid on Nov 24, 2023 going ex on Nov 09, 2023
Nov 10, 2023
Nov 24, 2023
Nov 09, 2023
Aug 08, 2023
TECH.NB Interim Cash Dividend of gross USD 0.08 paid on Sep 01, 2023 going ex on Aug 17, 2023
Aug 18, 2023
Sep 01, 2023
Aug 17, 2023
May 03, 2023
TECH.NB Interim Cash Dividend of gross USD 0.08 paid on May 26, 2023 going ex on May 12, 2023
May 15, 2023
May 26, 2023
May 12, 2023
Feb 02, 2023
TECH.NB Interim Cash Dividend of gross USD 0.08 paid on Feb 27, 2023 going ex on Feb 10, 2023
Feb 13, 2023
Feb 27, 2023
Feb 10, 2023
Nov 01, 2022
TECH.NB Final Cash Dividend of gross USD 0.32 paid on Nov 28, 2022 going ex on Nov 10, 2022
Nov 14, 2022
Nov 28, 2022
Nov 10, 2022
View more
Stock Split
Date
Type
Ratio
Nov 01, 2022
Split
1>4
Date
Type
Ratio
Nov 01, 2022
Split
1>4
